{"id":10499,"date":"2021-04-20T15:19:51","date_gmt":"2021-04-20T14:19:51","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=10499"},"modified":"2021-05-20T10:27:00","modified_gmt":"2021-05-20T09:27:00","slug":"deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/","title":{"rendered":"DEINOVE b\u00e9n\u00e9ficie du soutien de l\u2019Etat, dans le cadre du plan France Relance, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens"},"content":{"rendered":"\n<p>Communiqu\u00e9 de presse publi\u00e9 le 10 mars 2021 sur le <a href=\"https:\/\/www.deinove.com\/fr\/actualites\/tous-les-communiques\/deinove-beneficie-soutien-letat-dans-cadre-plan-france-relance-pour-accelerer-developpement-nouveaux-antimicrobiens\" target=\"_blank\" rel=\"noreferrer noopener\">site de DEINOVE<\/a><\/p>\n\n\n\n<ul><li>Son projet Boost-ID a \u00e9t\u00e9 s\u00e9lectionn\u00e9 dans le cadre du plan France Relance, une reconnaissance de sa dimension strat\u00e9gique.<\/li><li>Boost-ID est un acc\u00e9l\u00e9rateur dans l\u2019identification d\u2019antimicrobiens et de mol\u00e9cules d\u2019origine naturelle \u00e0 forte valeur ajout\u00e9e.<\/li><li>Boost-ID consiste en la mise en place d\u2019une plateforme de criblage haut-d\u00e9bit de bact\u00e9ries \u00e0 partir d\u2019une technologie de rupture : la microfluidique en gouttes.<\/li><li>C\u2019est l&#8217;un des six projets dans le secteur strat\u00e9gique de la sant\u00e9 retenus en Occitanie.<\/li><\/ul>\n\n\n\n<p><a href=\"https:\/\/www.deinove.com\/fr\" target=\"_blank\" rel=\"noreferrer noopener\">DEINOVE<\/a> (Euronext Growth Paris : ALDEI), soci\u00e9t\u00e9 de biotechnologie fran\u00e7aise pionni\u00e8re dans l\u2019exploration et l&#8217;exploitation de la biodiversit\u00e9 bact\u00e9rienne pour relever le d\u00e9fi urgent et plan\u00e9taire de la r\u00e9sistance aux antimicrobiens,<strong>&nbsp;annonce que son projet Boost-ID (Bacteria Optimum Output Screening Tool for treating Infectious Diseases) fait partie de 105 projets retenus par l\u2019Etat, sur pr\u00e8s de 1000 pr\u00e9sent\u00e9s, dans le cadre de l\u2019appel \u00e0 projet r\u00e9silience.<\/strong>&nbsp;<\/p>\n\n\n\n<p>La subvention, dont le montant devrait \u00eatre de 500 \u00e0 800 k\u20ac, est destin\u00e9e \u00e0 soutenir le projet Boost-ID, estim\u00e9 \u00e0 un peu plus de 1 M\u20ac au total, et permettra \u00e0 DEINOVE de mettre en place une station industrielle de tri de bact\u00e9ries \u00e0 tr\u00e8s haut d\u00e9bit, \u00e0 partir de la microfluidique en gouttes. Boost-ID s\u2019inscrit dans la continuit\u00e9 du projet Deinodrop[1] soutenu par l\u2019Agence Nationale de la Recherche (ANR).<\/p>\n\n\n\n<p>DEINOVE se dote ainsi d&#8217;une technologie de rupture, \u00e0 l&#8217;interface de la physique et de la biologie moderne. Boost-ID va acc\u00e9l\u00e9rer l\u2019isolement s\u00e9lectif de bact\u00e9ries \u00e0 fort potentiel antimicrobien \u00e0 partir d\u2019\u00e9chantillons environnementaux et deviendra la premi\u00e8re \u00e9tape de criblage de DEINOVE. <\/p>\n\n\n\n<p>La microfluidique est bas\u00e9e sur la manipulation de volumes infiniment petits (\u00e9chelle du picolitre ou 10-12 litre) et \u00e0 tr\u00e8s haut d\u00e9bit (1 million de bact\u00e9ries par heure). Boost-ID augmentera ainsi le rendement actuel de la plateforme tout en r\u00e9duisant ses co\u00fbts. Les souches bact\u00e9riennes aux activit\u00e9s les plus prometteuses, d\u00e9tect\u00e9es en microfluidique, passeront ensuite par les \u00e9tapes d&#8217;extraction automatis\u00e9e, n\u00e9cessitant des volumes plus importants, pour \u00eatre test\u00e9es sur des panels de r\u00e9f\u00e9rence. <\/p>\n\n\n\n<p>La large proportion de m\u00e9tabolites \u00e9tant de nature chimique trop complexe pour la chimie de synth\u00e8se, les capacit\u00e9s de bioproduction par fermentation et le savoir-faire de DEINOVE entreront alors en jeu pour obtenir les masse et qualit\u00e9 critiques pour leurs \u00e9valuations pr\u00e9cliniques et cliniques.<\/p>\n\n\n\n<p>Du picolitre au 20 litres, la Soci\u00e9t\u00e9 renforce donc sa position de biotech industrielle d\u00e9di\u00e9e \u00e0 l&#8217;identification de \u00ab&nbsp;p\u00e9pites&nbsp;\u00bb d&#8217;origine naturelle, \u00e0 partir de la mati\u00e8re noire microbienne \u00e0 99,9% inexplor\u00e9e[2]. Avec un gain de rendement majeur en amont du proc\u00e9d\u00e9, Boost-ID permettra d\u2019acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens et de mol\u00e9cules d\u2019origine naturelle \u00e0 forte valeur ajout\u00e9e.<\/p>\n\n\n\n<p><strong>Alexis Rideau, Directeur G\u00e9n\u00e9ral de DEINOVE commente&nbsp;:<\/strong><em>&nbsp;\u00ab&nbsp;Ce soutien de l\u2019Etat va acc\u00e9l\u00e9rer la mise en place de notre plateforme de microfluidique, avec l\u2019objectif d\u2019\u00eatre op\u00e9rationnels d\u00e8s la fin 2021. Boost-ID va d\u00e9cupler le rendement actuel de la plateforme tout en r\u00e9duisant ses co\u00fbts, notamment au niveau des r\u00e9actifs et des mati\u00e8res plastiques. Coupl\u00e9e \u00e0 notre expertise et nos capacit\u00e9s technologiques en biologie synth\u00e9tique, la microfluidique est un tournant dans l\u2019histoire de DEINOVE car elle va nous permettre de r\u00e9aliser des tests biologiques peu co\u00fbteux et \u00e0 des cadences in\u00e9gal\u00e9es pour explorer et exploiter la mati\u00e8re noire microbienne. \u00bb<\/em><\/p>\n\n\n\n<p>[1]&nbsp;<a href=\"https:\/\/www.deinove.com\/fr\/actualites\/tous-les-communiques\/deinove-et-lespci-paris-obtiennent-financement-lanr-pour-developper-technologie-deinodrop\" target=\"_blank\" rel=\"noreferrer noopener\">Communiqu\u00e9 du 9 d\u00e9cembre 2019<\/a><\/p>\n\n\n\n<p>[2]&nbsp;<a href=\"https:\/\/www.pnas.org\/content\/113\/21\/5970\" target=\"_blank\" rel=\"noreferrer noopener\">Kenneth J. Locey and Jay T. Lennon, Scaling laws predict global microbial diversity, PNAS May 24, 2016 113 (21) 5970-5975<\/a><\/p>\n\n\n\n<p>Download the English version <a href=\"https:\/\/www.deinove.com\/sites\/default\/files\/pdf_news\/210310_deinove_pr_plan_de_relance.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">on this link<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Le projet Boost ID de la biotech montpelli\u00e9raine Deinove\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/8MY8bXmK4lk?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Communiqu\u00e9 de presse publi\u00e9 le 10 mars 2021 sur le site de DEINOVE Son projet Boost-ID a \u00e9t\u00e9 s\u00e9lectionn\u00e9 dans le cadre du plan France Relance, une reconnaissance de sa dimension strat\u00e9gique. Boost-ID est un acc\u00e9l\u00e9rateur dans l\u2019identification d\u2019antimicrobiens et de mol\u00e9cules d\u2019origine naturelle \u00e0 forte valeur ajout\u00e9e. Boost-ID consiste en la mise en place [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":10523,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>DEINOVE b\u00e9n\u00e9ficie du soutien de l\u2019Etat, dans le cadre du plan France Relance, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DEINOVE b\u00e9n\u00e9ficie du soutien de l\u2019Etat, dans le cadre du plan France Relance, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-20T14:19:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-20T09:27:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Marecage.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"DEINOVE b\u00e9n\u00e9ficie du soutien de l\u2019Etat, dans le cadre du plan France Relance, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens\",\"datePublished\":\"2021-04-20T14:19:51+00:00\",\"dateModified\":\"2021-05-20T09:27:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/\"},\"wordCount\":674,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Marecage.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/\",\"name\":\"DEINOVE b\u00e9n\u00e9ficie du soutien de l\u2019Etat, dans le cadre du plan France Relance, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Marecage.jpg\",\"datePublished\":\"2021-04-20T14:19:51+00:00\",\"dateModified\":\"2021-05-20T09:27:00+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Marecage.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Marecage.jpg\",\"width\":500,\"height\":242,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"DEINOVE b\u00e9n\u00e9ficie du soutien de l\u2019Etat, dans le cadre du plan France Relance, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DEINOVE b\u00e9n\u00e9ficie du soutien de l\u2019Etat, dans le cadre du plan France Relance, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/","og_locale":"en_GB","og_type":"article","og_title":"DEINOVE b\u00e9n\u00e9ficie du soutien de l\u2019Etat, dans le cadre du plan France Relance, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2021-04-20T14:19:51+00:00","article_modified_time":"2021-05-20T09:27:00+00:00","og_image":[{"width":500,"height":242,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Marecage.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"DEINOVE b\u00e9n\u00e9ficie du soutien de l\u2019Etat, dans le cadre du plan France Relance, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens","datePublished":"2021-04-20T14:19:51+00:00","dateModified":"2021-05-20T09:27:00+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/"},"wordCount":674,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Marecage.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/","name":"DEINOVE b\u00e9n\u00e9ficie du soutien de l\u2019Etat, dans le cadre du plan France Relance, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Marecage.jpg","datePublished":"2021-04-20T14:19:51+00:00","dateModified":"2021-05-20T09:27:00+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Marecage.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Marecage.jpg","width":500,"height":242,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/deinove-beneficie-du-soutien-de-letat-dans-le-cadre-du-plan-france-relance-pour-accelerer-le-developpement-de-nouveaux-antimicrobiens\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"News","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/"},{"@type":"ListItem","position":4,"name":"DEINOVE b\u00e9n\u00e9ficie du soutien de l\u2019Etat, dans le cadre du plan France Relance, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de nouveaux antimicrobiens"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-13 08:59:56","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/10499"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=10499"}],"version-history":[{"count":12,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/10499\/revisions"}],"predecessor-version":[{"id":10525,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/10499\/revisions\/10525"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/10523"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=10499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=10499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=10499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}